Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM)
AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety
Study of Oral MDV3100 in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Category & Conditions: Cancer
Medicine: Xtandi (enzalutamide)
ClinicalTrials.gov Identifier (NCT): NCT00974311
Protocol ID: C3431010
PrintDownloadOpen Plain Language Summary Result: Click here